Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.6% Today

What is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ: AMLX) is a pharmaceutical company specialized in developing treatments for post-bariatric hypoglycemia (PBH). The company's primary focus is on AVEXITIDE, currently undergoing Phase 3 trials with encouraging outcomes.

Why is Amylyx Pharmaceuticals going down?

AMLX stock is down 5.6% on May 15, 2026 14:36

• The upcoming Phase 3 AVEXITIDE trial results in the third quarter failed to offset the negative impact of Amylyx Pharmaceuticals' Q1 2026 earnings miss, resulting in a significant drop in the stock price.
• Despite the favorable prospects for AVEXITIDE and the company's robust financial standing, the earnings miss brought forth investor worries regarding the current financial performance.
• Differing viewpoints on the valuation of Amylyx Pharmaceuticals emerged, as a DCF analysis suggested undervaluation while the P/B ratio indicated overvaluation, likely playing a role in the bearish market behavior as investors reevaluate the stock's true value.
• The substantial valuation discrepancy between the stock price and analyst predictions, notwithstanding the positive advancements with AVEXITIDE and strategic investments in R&D, might have intensified the downward momentum on AMLX shares.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus

Amylyx Pharmaceuticals (NASDAQ: AMLX) is anticipating the Phase 3 LUCIDITY trial readout for its lead asset, AVEXITIDE, which treats post-bariatric hypoglycemia (PBH), in the third quarter. Co-CEO Joshua Cohen highlighted the trial's design to replicate earlier successful studies and its focus on an underserved patient population with no approved therapies. If positive, Amylyx plans a rapid New Drug Application submission, aiming for a 2027 launch, supported by its Breakthrough Therapy designation and strong financial position.

https://www.inkl.com/news/amylyx-pharmaceuticals-eyes-phase-3-avexitide-readout-as-2027-launch-comes-into-focus

Earnings call transcript: Amylyx Pharmaceuticals Q1 2026 earnings miss impacts stock

Amylyx Pharmaceuticals reported a Q1 2026 loss per share of $0.37, missing analyst expectations of $0.33, leading to an 8.28% stock price decline. The company is advancing its pivotal Phase III LUCIDITY trial for avexitide, an investigational drug for post-bariatric hypoglycemia (PBH), with top-line results expected in Q3 2026 and a potential commercial launch in 2027. Despite the earnings miss, Amylyx maintains a cash runway into 2028 and continues to emphasize strategic investments in R&D and commercial readiness for avexitide, which addresses an unmet need for PBH patients.

https://www.investing.com/news/transcripts/earnings-call-transcript-amylyx-pharmaceuticals-q1-2026-earnings-miss-impacts-stock-93CH-4685734

Is It Too Late To Consider Amylyx Pharmaceuticals (AMLX) After A 220% One Year Surge?

Amylyx Pharmaceuticals (AMLX) has surged 220.2% over the past year, prompting an evaluation of its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued at $14.73, with an estimated intrinsic value of $48.59. However, its Price-to-Book (P/B) ratio of 5.99x indicates it is overvalued compared to the industry average of 2.70x, pointing to differing perspectives on its true worth.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/is-it-too-late-to-consider-amylyx-pharmaceuticals-amlx-after

Amylyx Readies Avexitide For PBH With Pivotal Trial And Valuation Gap

Amylyx Pharmaceuticals (AMLX) is advancing its lead candidate, avexitide, through the pivotal Phase III LUCIDITY trial for post-bariatric hypoglycemia (PBH), with data expected next quarter. The company has also initiated an expanded access program for avexitide. Despite recent stock weakness, its shares are trading significantly below the consensus target and Simply Wall St's fair value estimate, indicating a large valuation gap.

https://www.sahmcapital.com/news/content/amylyx-readies-avexitide-for-pbh-with-pivotal-trial-and-valuation-gap-2026-05-10

Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Annexon Biosciences (ANNX) and AMN Healthcare Services (AMN)

Healthcare sector analysts have recently provided new ratings for Amylyx Pharmaceuticals Inc (AMLX), Annexon Biosciences (ANNX), and AMN Healthcare Services (AMN). Amylyx and Annexon Biosciences received Buy ratings with significant upside potential from H.C. Wainwright, while AMN Healthcare Services was given a Hold rating by William Blair. These ratings reflect varied outlooks on the companies' stock performance.

https://www.theglobeandmail.com/investing/markets/stocks/AMN/pressreleases/1828237/analysts-offer-insights-on-healthcare-companies-amylyx-pharmaceuticals-inc-amlx-annexon-biosciences-annx-and-amn-healthcare-services-amn/

Trending Today

Advance Auto Parts Inc W/I ($AAP) Stock Forecast: Down 5.1% Today

NRG Energy Inc. ($NRG) Stock Forecast: Down 5.0% Today

Ubiquiti ($UI) Stock Forecast: Down 5.2% Today

Franco-Nevada Corp. ($FNV) Stock Forecast: Down 5.2% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Up 11.1% Today

Ford Motor Company ($F) Stock Forecast: Down 7.1% Today

ServiceNow Inc. ($NOW) Stock Forecast: Up 5.0% Today

Kornit Digital Ltd. ($KRNT) Stock Forecast: Down 5.4% Today

Aptiv PLC ($APTV) Stock Forecast: Down 5.0% Today

Teradyne, Inc. ($TER) Stock Forecast: Down 5.6% Today

Amylyx Pharmaceuticals Price History

07.03.2026 - AMLX Stock was up 5.0%

• AMLX shares surged by 6.66% on April 6, driven by positive investor sentiment and analyst recommendations pointing towards a potential upside.
• The 7.8% drop following the earnings report showing $0 revenue and concerns over stock dilution from a shelf filing led to a brief decline in the stock price.
• The completion of enrollment and dosing for the pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia is a crucial milestone for AMLX, with the outcome expected to shape the company's future revenue prospects and investment narrative.
• Overall, the bullish movement today can be attributed to a mix of positive analyst outlook, milestone achievements in clinical trials, and short-term market reactions to earnings and dilution concerns.

30.02.2026 - AMLX Stock was down 5.5%

• The bearish movement in AMLX's stock price today can be attributed to a realignment of holdings by a major investment firm, resulting in the firm reporting 0% beneficial ownership of AMLX common stock. This change may have caused uncertainty among investors, leading to a sell-off of the stock.
• Despite analysts on Wall Street maintaining a bullish sentiment on AMLX and reiterating Buy ratings with optimistic price targets, the sudden change in the investment firm's ownership status likely overshadowed these positive recommendations.
• Additionally, the discontinuation of the ORION program for AMX0035, as highlighted in recent SEC filings, could have raised concerns among investors about the company's future pipeline and potential revenue streams, contributing to the bearish market movement.

15.04.2026 - AMLX Stock was down 5.6%

• The upcoming Phase 3 AVEXITIDE trial results in the third quarter failed to offset the negative impact of Amylyx Pharmaceuticals' Q1 2026 earnings miss, resulting in a significant drop in the stock price.
• Despite the favorable prospects for AVEXITIDE and the company's robust financial standing, the earnings miss brought forth investor worries regarding the current financial performance.
• Differing viewpoints on the valuation of Amylyx Pharmaceuticals emerged, as a DCF analysis suggested undervaluation while the P/B ratio indicated overvaluation, likely playing a role in the bearish market behavior as investors reevaluate the stock's true value.
• The substantial valuation discrepancy between the stock price and analyst predictions, notwithstanding the positive advancements with AVEXITIDE and strategic investments in R&D, might have intensified the downward momentum on AMLX shares.

29.03.2026 - AMLX Stock was down 5.1%

• The downward movement in AMLX stock today might be due to profit-taking by investors following several price target upgrades by different financial institutions. It is possible that traders decided to sell to secure profits after positive changes were made to the price targets.
• Despite the positive outlook from analysts and the excitement surrounding the Phase 3 LUCIDITY study data for avexitide, the market response today could indicate a short-term decline in the stock price.
• The reduction in the Co-CEO and Director's 2025 compensation compared to the previous year may also play a role in the negative sentiment towards the stock, potentially raising concerns about internal stability or performance expectations within the company.

28.03.2026 - AMLX Stock was down 5.2%

• The bearish movement in AMLX stock today could be attributed to the significant decrease in compensation for both Co-CEOs and Directors, Justin Klee and Joshua Cohen, as revealed in the recent SEC DEF14A filings. This unexpected decrease in executive pay may have raised concerns among investors about the company's financial performance or future prospects.
• Investors might be reacting to the upcoming Q3 2025 earnings preview, anticipating potentially disappointing financial results. The market sentiment could be influenced by expectations set by analysts and insiders' activities.
• Insider trading activities, hedge fund movements, and analyst ratings could have also contributed to the negative market sentiment surrounding AMLX stock, leading to the bearish movement observed today.

28.03.2026 - AMLX Stock was down 5.1%

• An increased price target for AMLX was influenced by a reduced expense forecast, potentially boosting investor confidence initially.
• However, concerns arose over the reduced compensation of the Co-CEO and Director in 2025, prompting doubts about the company's financial well-being and future prospects, leading to the bearish market movement.
• The impending Q3 2025 earnings preview may also be contributing to investor unease and stock selling pressure.
• In summary, despite positive adjustments to the price target, the news about reduced executive compensation and the upcoming earnings report could have dampened optimism, resulting in the decline of AMLX stock.

06.03.2026 - AMLX Stock was up 5.1%

• AMLX experienced a notable 3.52% increase in share price on April 2nd, despite reporting $0 revenue in its recent earnings.
• The positive market response could be linked to the successful enrollment and dosing completion of its pivotal Phase 3 LUCIDITY trial, marking a significant achievement for the company.
• Investor confidence in the potential success of avexitide for post-bariatric hypoglycemia, demonstrated by the trial enrollment completion, likely influenced the bullish movement.
• Concerns about stock dilution after the shelf filing appear to have been outweighed by favorable developments in the company's clinical trials, prompting the upward trend in the stock price.

12.04.2026 - AMLX Stock was down 5.2%

• A Discounted Cash Flow (DCF) analysis suggests AMLX is significantly undervalued, but its Price-to-Book (P/B) ratio indicates overvaluation compared to industry peers.
• Despite positive developments like completing enrollment for a pivotal trial and initiating an Expanded Access Program, AMLX's stock is trading below consensus targets and fair value estimates, leading to a large valuation gap.
• Analysts have provided varied ratings on AMLX, reflecting differing outlooks on the company's stock performance.
• The overall bearish movement in the healthcare sector, as evidenced by other healthcare stocks experiencing significant decreases in the pre-market session, could have contributed to AMLX's downward trend today.

07.04.2026 - AMLX Stock was down 6.9%

• The decline in AMLX stock today could be linked to the anticipation of the company's first-quarter financial results, which are projected to show a per-share loss and no revenue. This financial performance may have disappointed investors.
• Furthermore, the market's reaction to the news about the upcoming Phase 3 LUCIDITY trial data for avexitide, crucial for the company's future valuation and cash position, may have added to the negative sentiment.
• Amylyx Pharmaceuticals' involvement in investor conferences could have also impacted market sentiment, as investors may be waiting for insights or updates from these events before making significant decisions regarding the stock.
• Overall, factors such as financial performance expectations, forthcoming trial data, and participation in investor conferences likely contributed to the bearish movement in AMLX stock today.

14.03.2026 - AMLX Stock was up 5.3%

• The bullish movement in AMLX stock could be attributed to the selection of AMX0318 as a new development candidate, indicating progress in the company's pipeline for treating neurodegenerative diseases.
• The upcoming presentation at the 25th Annual Needham Virtual Healthcare Conference might have generated positive investor sentiment, as it provides a platform for the company to showcase its innovative therapies and potential market opportunities.
• Despite the investigation into potential breaches of fiduciary duties by insiders, investors seem optimistic about the company's future prospects, possibly due to the focus on addressing diseases with high unmet needs and the positive market analysis reports.
• Overall, the combination of positive corporate developments, upcoming conference presentation, and market analysis highlighting growth potential could have fueled the bullish momentum in AMLX stock today.

10.03.2026 - AMLX Stock was down 5.1%

• The bearish movement in AMLX's stock price could be attributed to the ongoing investigation into potential breaches of fiduciary duties by the company's officers and directors. This uncertainty may have led to a lack of investor confidence in the stock.
• Additionally, despite the positive news of AMLX's participation in the 25th Annual Needham Virtual Healthcare Conference to showcase its development candidates, the market may have reacted negatively to the lack of concrete updates or significant announcements during the event.
• The insider trading activities disclosed in the SEC filings, including stock sales for tax obligations and gifts, might have also contributed to the downward pressure on AMLX's stock price as investors may interpret these actions as a lack of long-term confidence in the company's prospects.
• Overall, the combination of legal investigations, lack of significant updates from the healthcare conference, and insider trading activities could have collectively influenced the bearish market movement in AMLX today.

17.03.2026 - AMLX Stock was up 5.4%

• Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) received a "Moderate Buy" recommendation from brokerages, indicating positive sentiment towards the stock.
• The company reported quarterly earnings that slightly beat analyst estimates, contributing to the bullish movement in the stock.
• Insider transactions, such as recent sales by the CEO, and adjustments in holdings by institutional investors may have influenced market confidence in the company's future prospects, driving the bullish movement in the stock.